The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Solifenacin succinate/Tamsulosin hydrochloride Rowex 6 mg/0.4 mg modified-release tablets



Rowex LtdPA0711/317/001

Main Information

Trade NameSolifenacin succinate/Tamsulosin hydrochloride Rowex 6 mg/0.4 mg modified-release tablets
Active SubstancesSolifenacin succinate
Tamsulosin hydrochloride
Dosage FormModified-release tablet
Licence HolderRowex Ltd
Licence NumberPA0711/317/001

Group Information

ATC CodeG04CA53 tamsulosin and solifenacin

Status

License statusAuthorised
Licence Issued26/05/2023
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0101-154-021
Interchangeable List DocumentPDF of Interchangeable List
« Back